SCHEMBL5235362

SCHEMBL5235362

CC(C)Cn1c(N(C)C(=O)O)c(-c2ccccc2)c2cc(S(C)(=O)=O)ccc2c1=O

nearest known ligand 0.50

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 17/20 0.50
MAPK8 P45983 3/20 0.46
MAPK9 P45984 1/20 0.44
MAPK10 P53779 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5237906 0.85 DPP4 (0.65) DPP4
SCHEMBL5235642 0.85 DPP4 (0.47) DPP4MAPK8
SCHEMBL5234802 0.85 DPP4 (0.64) DPP4MAPK8
SCHEMBL5234230 0.85 DPP4 (0.52) DPP4
SCHEMBL5237616 0.84 DPP4 (0.59) DPP4
SCHEMBL5231521 0.84 DPP4 (0.59) DPP4
SCHEMBL5238176 0.83 DPP4 (0.51) DPP4
SCHEMBL5233349 0.83 DPP4 (0.54) DPP4
SCHEMBL5234135 0.82 DPP4 (0.57) DPP4
SCHEMBL5233990 0.82 DPP4 (0.66) DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1355886-B1 FUSED HETEROCYCLIC COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2007-07-11 EP disclosed
US-20040082607-A1 Fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082607-A1 Fused heterocyclic compounds DPP7, DPP4, METAP1 DPP4 2/4885MAPK8 2612/4885MAPK9 3393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.